CHPG NEW
| Price | Get Latest Price |
| Package | 1removed |
| Supply Ability: | 10g |
| Update Time: | 2026-07-27 |
Product Details
| Product Name: CHPG | CAS No.: 170846-74-9 |
| Supply Ability: 10g | Release date: 2026/07/27 |
Product Introduction
Bioactivity
| Name | CHPG |
| Description | CHPG is a selective mGluR5 agonist that reduces LDH release and neuronal apoptosis, activates the ERK and Akt pathways, and protects against traumatic brain injury. It also increases the number of differentiated human OPCs and alleviates LPS-induced inflammation. |
| In vitro | Methods: The study used BV2 microglial cells to investigate the protective effects of CHPG against SO? derivative-induced damage. Cells were treated with CHPG at concentrations of 10–500 μM for 24 hours to assess cell viability and LDH release. In another set of experiments, cells were treated with 0.5 mM CHPG for 30 minutes to evaluate its effects on SO?-induced apoptosis and the expression levels of TSG-6 at both mRNA and protein levels. Results: CHPG significantly enhanced the viability of BV2 cells, reduced LDH release, and alleviated cellular damage caused by SO? derivatives. Additionally, CHPG inhibited SO?-induced apoptosis and upregulated the expression of TSG-6 at both mRNA and protein levels, indicating its potential neuroprotective effects. [1] |
| In vivo | Methods: The study used adult male Sprague-Dawley rats weighing 280–320 g, which were injected with 250 nM CHPG daily for 7 consecutive days to evaluate its effect on cerebral lesion volume. Results: CHPG treatment significantly reduced cerebral lesion volume in rats, indicating potential neuroprotective effects. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 20 mg/mL (99.2 mM), when pH is adjusted to 2 with 1M HCL. 1M NaOH : 20 mg/mL (99.2 mM), when pH is adjusted to 11 with NaOH. Sonication is recommended. |
| Keywords | NF-κB | mGlu5 | CHPG |
| Inhibitors Related | Aceglutamide | Urea | Chitin | L-Cysteine | Kojic acid | Triphenyl phosphate | Ethyl linoleate | D-Psicose | 5-Aminosalicylic Acid | Zinc chloride | Gluconate Calcium | Gluconate sodium |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | NF-κB Signaling Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Kinase Inhibitor Library | Neurotransmitter Receptor Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library | MAPK Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:1303993-73-8
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $31.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-08-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY